The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

What is Neuromodulation?

Breaking News Share

Clinical Data Presented Regarding Two Companies' Neuromodulation Devices

Jan. 12, 2018 - An article covers announcements by Medtronic plc and Boston Scientific Corporation about studies the companies presented at the annual meeting of the North American Neuromodulation Society. Medtronic announced results of its Sisters study that compared treatment for spasticity after a stroke using either oral baclofen or baclofen delivered intrathecally with the company's implantable intrathecal drug delivery system, SynchroMed II. Boston Scientific presented data from its randomized controlled clinical trial, Whisper. The data showed a difference in how many patients could effectively control their pain with the company's Precision spinal cord stimulation device by either being limited to a single stimulation mode or having a choice of two different stimulation modes.

Company Announces Presentation of Data from Studies of High-Frequency Spinal Cord Stimulation

Jan. 12, 2018 - Nevro Corp. announced presentations at the annual meeting of the North American Neuromodulation Society. These include data regarding a study of the company's high-frequency spinal cord stimulation in intractable neck and/or upper limb pain; a study of the device in peripheral polyneuropathy that has led to a new trial in painful diabetic neuropathy; and a study in non-surgical refractory back pain. (Medical Device News Magazine)

FDA Approval Announced for Spinal Cord Stimulator that Varies Frequency, Pulse Width, and Amplitude

Jan. 11, 2018 - Boston Scientific Corporation announced pre-market approval from the FDA for its spinal cord stimulation device that permits varying frequency, pulse width and amplitude, the Spectra WaveWriter. (Mass Device)

Peripheral Nerve Stimulator Data Presented in Poster Sessions

Jan. 11, 2018 - Bioness, Inc. announced that data from four studies will be presented during poster sessions at the annual meeting of the North American Neuromodulation Society about its peripheral nerve stimulator, StimRouter. The studies concern use of the device for chronic pain originating from the peripheral nerve region of the shoulder, tibia and other areas of the body. (Markets Insider)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM